Acceleron might have a second drug on its hands
Acceleron Pharma said its in-development treatment for pulmonary arterial hypertension met all its goals in a mid-stage study, news that sent the company’s stock price up more than 50% in after-hours trading last night.
As STAT’s Adam Feuerstein reports, Acceleron’s drug improved patients’ blood flow and boosted scores on a walking test, according to the company, which is saving detailed data for a later medical meeting. If the results hold up, they’ll inform the design of a later study that would support FDA approval.
That’s a key step for Acceleron, which has struggled to win plaudits for its pipeline after winning approval last year for a drug targeting the rare blood disease beta thalassemia.
Read more.
As STAT’s Adam Feuerstein reports, Acceleron’s drug improved patients’ blood flow and boosted scores on a walking test, according to the company, which is saving detailed data for a later medical meeting. If the results hold up, they’ll inform the design of a later study that would support FDA approval.
That’s a key step for Acceleron, which has struggled to win plaudits for its pipeline after winning approval last year for a drug targeting the rare blood disease beta thalassemia.
Read more.
.png)
No hay comentarios:
Publicar un comentario